Skip to main content
    C

    Clearside Biomedical Inc (CLSD)

    Official site

    BIOTECHNOLOGY

    $0.41
    +0.00 (+0.00%)

    Last updated: Nov 13, 2026 at 4:00 PM ET

    Clearside Biomedical Inc (CLSD) Financials: Revenue, Profit and Cash Flow

    Updated Nov 18, 2025. Financial statements from company filings, amounts in US dollars.

    Clearside Biomedical reported revenue of $1.66M for the fiscal year ended Dec 31, 2024, down 79.8% from the year before. That year, net income was -$34.35M with a net margin of -2064.4%, operating cash flow was -$24.70M and free cash flow was -$25.68M. The quarter ended Sep 30, 2025 had revenue of $201.00K and net income of -$5.97M.

    Revenue and Margins

    Over the 8 years to Dec 2024, revenue grew from $520.00K, a compound annual rate of 15.6%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2024$1.66M-79.8%91.0%-1735.7%-2064.4%
    Dec 2023$8.23M+519.9%95.7%-302.0%-394.9%
    Dec 2022$1.33M-95.5%84.6%-2281.6%-2482.8%
    Dec 2021$29.57M+274.7%100.0%-2.1%1.3%
    Dec 2020$7.89M+263.3%100.0%-227.2%-228.4%
    Dec 2019$2.17M+7143.3%100.0%-1394.6%-1406.3%
    Dec 2018$30.00K-91.3%100.0%-276483.3%-276060.0%
    Dec 2017$345.00K-33.7%100.0%-16929.9%-17094.2%
    Dec 2016$520.00KN/A100.0%-4845.8%-4977.3%
    Dec 2015$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2015 to Dec 2024

    Income Statement

    In the fiscal year ended Dec 2024, the net loss widened from the year before. In the quarter ended Sep 2025, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015
    Revenue$1.66M$8.23M$1.33M$29.57M$7.89M$2.17M$30.00K$345.00K$520.00K$0
    Cost of revenue$149.00K$355.00K$204.00K$178.00K$0N/A$0$58.57M$25.65M$33.00K
    Gross profit$1.51M$7.87M$1.12M$29.57M$7.89M$2.17M$30.00K$345.00K$520.00K-$33.00K
    Research and development$18.59M$20.85M$19.63M$18.54M$15.07M$15.66M$68.29M$49.05M$19.45M$10.76M
    Operating income-$28.88M-$24.84M-$30.28M-$627.00K-$17.93M-$30.30M-$82.94M-$58.41M-$25.20M-$17.32M
    Net income-$34.35M-$32.48M-$32.95M$376.00K-$18.03M-$30.56M-$82.82M-$58.98M-$25.88M-$17.64M
    EBITDA-$24.35M-$23.06M-$29.46M$554.00K-$17.75M-$30.09M-$82.76M-$58.23M-$25.13M-$17.26M
    Fiscal years ended Dec 2015 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Revenue$201.00K$492.00K$2.33M$306.00K$1.04M$90.00K$230.00K$6.34M$859.00K$1.02M$4.00K$330.00K
    Gross profit$201.00K$408.00K$2.08M$157.00K$1.04M$90.00K$202.00K$6.33M$717.00K$805.00K$4.00K$126.00K
    Operating income-$7.04M-$3.57M-$5.21M-$7.15M-$5.93M-$7.59M-$8.21M-$2.92M-$7.05M-$7.27M-$7.61M-$8.07M
    Net income-$5.97M-$4.50M-$8.22M-$7.31M-$7.69M-$7.59M-$11.76M-$4.83M-$9.27M-$9.11M-$9.28M-$8.59M
    Last 12 quarters

    Balance Sheet

    As of Dec 2024, cash and equivalents of $20.02M were 79.7% of total assets of $25.13M, against total liabilities of $63.98M.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015
    Total assets$25.13M$34.02M$51.30M$42.90M$19.32M$26.78M$44.12M$40.49M$84.81M$21.05M
    Current assets$21.27M$30.12M$49.40M$42.14M$18.12M$25.22M$42.94M$37.64M$83.63M$20.48M
    Cash and equivalents$20.02M$28.92M$48.26M$30.44M$17.29M$22.59M$8.04M$9.22M$34.82M$20.28M
    Total liabilities$63.98M$49.93M$40.70M$4.93M$10.56M$15.62M$20.50M$19.08M$13.15M$57.71M
    Long-term debtN/AN/AN/AN/AN/A$3.82M$9.42M$4.81M$7.59M$4.24M
    Shareholder equity-$38.85M-$15.91M$10.61M$37.98M$8.76M$11.16M$23.62M$21.41M$71.66M-$36.66M
    Fiscal years ended Dec 2015 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Total assets$11.64M$15.33M$19.67M$25.13M$29.16M$33.93M$40.14M$34.02M$34.42M$39.19M$44.70M$51.30M
    Total liabilities$65.59M$64.07M$65.58M$63.98M$63.95M$62.22M$61.95M$49.93M$47.27M$44.16M$41.99M$40.70M
    Cash and equivalents$6.80M$9.38M$13.63M$20.02M$13.89M$18.24M$35.35M$28.92M$28.80M$35.01M$41.42M$48.26M
    Shareholder equity-$53.95M-$48.73M-$45.91M-$38.85M-$34.79M-$28.29M-$21.81M-$15.91M-$12.85M-$4.97M$2.70M$10.61M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2024.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015
    Operating cash flow-$24.70M-$18.14M-$13.37M-$10.73M-$13.12M-$27.07M-$79.20M-$51.08M-$22.71M-$13.90M
    Capital expenditures$977.00K$1.78M$246.00K$246.00K$55.00K$25.00K$88.00K$306.00K$3.00K$32.00K
    Free cash flow-$25.68M-$19.91M-$13.61M-$10.98M-$13.18M-$27.09M-$79.29M-$51.39M-$22.71M-$13.93M
    Dividends paidN/AN/AN/AN/AN/AN/AN/A$0$308.00KN/A
    Investing cash flow-$638.00K-$1.78M-$246.00K-$246.00K-$55.00K$32.92M-$3.76M$20.12M-$49.14M-$28.00K
    Financing cash flow$16.44M$414.00K$31.33M$23.78M$7.87M$8.70M$81.78M$5.36M$86.39M$25.94M
    Fiscal years ended Dec 2015 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Operating cash flow-$5.48M-$4.73M-$5.83M-$5.25M-$5.91M-$5.68M-$7.85M$495.00K-$6.08M-$5.34M-$7.22M-$5.61M
    Capital expenditures$9.00K$0$9.00K$444.00K$53.00K$423.00K$57.00K$120.00K$445.00K$1.10M$115.00K$91.00K
    Free cash flow-$5.49M-$4.73M-$5.84M-$5.70M-$5.97M-$6.10M-$7.91M$375.00K-$6.52M-$6.44M-$7.33M-$5.70M
    Last 12 quarters

    Frequently Asked Questions About CLSD

    What is Clearside Biomedical's annual revenue?

    Clearside Biomedical reported revenue of $1.66M for the fiscal year ended Dec 31, 2024.

    How fast is Clearside Biomedical's revenue growing?

    Revenue was down 79.8% for the fiscal year ended Dec 31, 2024 compared with the year before. The compound annual revenue growth rate over 3 years was -61.7%.

    Is Clearside Biomedical profitable?

    No. Clearside Biomedical reported net income of -$34.35M for the fiscal year ended Dec 31, 2024, with a net margin of -2064.4%.

    How much free cash flow does CLSD generate?

    For the fiscal year ended Dec 31, 2024, operating cash flow of -$24.70M minus capital expenditures of $977.00K produced free cash flow of -$25.68M.

    How much debt does Clearside Biomedical have?

    The balance sheet dated Dec 31, 2024 reported cash and equivalents of $20.02M.